{"text": "sage biib sage therapeutics and biogen announce sage 324 phase 2 placebo controlled kinetic study in essential tremor met primary endpoint business wire"}
{"text": "biib and sage safety profile of sage 324 is a big concern dose reduction in 62 of patients and 38 discontinued treatment somnolence 68 dizziness 38 balance disorder 15 diplopia 12 dysarthria 12"}
{"text": "serious dropout rate sage touts first win in 3b biogen pact but safety profile doubts over data cloud road ahead sage 6 biib"}
{"text": "biogen sage s drug reduces upper limb tremor but tolerability issues arise biib sage"}
{"text": "biogen biib given new 245 00 price target at wedbush markets"}
{"text": "biogen biib given new 245 00 price target at wedbush stocks"}
